Mahadi Baig

1.1k total citations
42 papers, 344 citations indexed

About

Mahadi Baig is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mahadi Baig has authored 42 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Mahadi Baig's work include Lung Cancer Treatments and Mutations (12 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Renal cell carcinoma treatment (7 papers). Mahadi Baig is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Renal cell carcinoma treatment (7 papers). Mahadi Baig collaborates with scholars based in United States, United Kingdom and Spain. Mahadi Baig's co-authors include Corina E. Dutcus, Shahzad Raza, Andrew G. Gianoukakis, Matthew Guo, Nicolas Batty, Barbara J. Berger, Helena Russell, Thomas E. Hutson, Abdul Hakeem and Khalid Mahmood and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Mahadi Baig

36 papers receiving 337 citations

Peers

Mahadi Baig

ONCOL

PRM

SURGE

Sang-Min Kim South Korea

A. Torres Spain

Tariq Kewan United States

Chiara Barbieri Italy

Alphan Küpesiz Türkiye

Laura Iliescu Romania

Michael P. Gailey United States

Manas Kumar Behera India

Girish Subbarao United States

Sang-Min Kim South Korea

Mahadi Baig

90 ×1.0

ONCOL

82 ×1.0

PRM

40 ×0.5

SURGE

61 ×0.8

24 ×0.4

Citations per year, relative to Mahadi Baig Mahadi Baig (= 1×) peers Sang-Min Kim

Countries citing papers authored by Mahadi Baig

Since Specialization

Citations

This map shows the geographic impact of Mahadi Baig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mahadi Baig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mahadi Baig more than expected).

Fields of papers citing papers by Mahadi Baig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mahadi Baig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mahadi Baig. The network helps show where Mahadi Baig may publish in the future.

Co-authorship network of co-authors of Mahadi Baig

This figure shows the co-authorship network connecting the top 25 collaborators of Mahadi Baig. A scholar is included among the top collaborators of Mahadi Baig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mahadi Baig. Mahadi Baig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lim, Sun Min, Jianjun Zhang, Nir Peled, et al.. (2025). 58P: Subcutaneous (SC) after intravenous (IV) amivantamab in advanced NSCLC: Initial results from PALOMA-2. Journal of Thoracic Oncology. 20(3). S46–S47.

Daneshmand, Siamak, Renata Zaucha, James W.F. Catto, et al.. (2025). Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study. European Urology. 89(2). 165–173.

Daneshmand, Siamak, Renata Zaucha, Nikhil Vasdev, et al.. (2024). MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS. Urologic Oncology Seminars and Original Investigations. 42. S58–S58. 1 indexed citations

Leighl, Natasha B., Hiroaki Akamatsu, Ying Cheng, et al.. (2024). Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA8505–LBA8505. 12 indexed citations

Spira, Alexander I., Byoung Chul Cho, Sang-We Kim, et al.. (2024). Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study.. Journal of Clinical Oncology. 42(16_suppl). 8619–8619. 3 indexed citations

Lim, Sun Min, Josiane Mourão Dias, Pei Jye Voon, et al.. (2024). Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.. Journal of Clinical Oncology. 42(17_suppl). LBA8612–LBA8612. 3 indexed citations

Zhou, Caicun, Akira Ono, Hidetoshi Hayashi, et al.. (2024). 635P Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC. Annals of Oncology. 35. S1638–S1639. 1 indexed citations

Cho, Byoung Chul, Yongsheng Wang, Enriqueta Felip, et al.. (2024). Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2.. Journal of Clinical Oncology. 42(16_suppl). 8516–8516. 12 indexed citations

Liu, Baogang, Yao Yu, Yanqiu Zhao, et al.. (2024). Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.. Journal of Clinical Oncology. 42(16_suppl). 8606–8606. 1 indexed citations

10.

Zhou, Caicun, Kun Tang, S-W. Kim, et al.. (2023). 513MO Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysis. Annals of Oncology. 34. S1668–S1669. 1 indexed citations

11.

Breyer, Johannes, Manish Monga, Roman Mayr, et al.. (2020). 758P Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC). Annals of Oncology. 31. S587–S588. 1 indexed citations

12.

Gianoukakis, Andrew G., Corina E. Dutcus, Nicolas Batty, Matthew Guo, & Mahadi Baig. (2018). Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocrine Related Cancer. 25(6). 699–704. 68 indexed citations

13.

Copher, Ronda, et al.. (2016). Understanding real world treatment patterns, healthcare resource utilization (HRU) and costs among metastatic renal cell carcinoma (mRCC) patients. Annals of Oncology. 27. vi355–vi355.

14.

Raza, Shahzad, et al.. (2015). A Prospective Study on Red Blood Cell Transfusion Related Hyperkalemia in Critically Ill Patients. Journal of Clinical Medicine Research. 7(6). 417–421. 20 indexed citations

15.

Augustine, Titto, Mahadi Baig, Temuri Budagov, et al.. (2014). Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. British Journal of Cancer. 112(2). 313–318. 19 indexed citations

16.

Raza, Shahzad, et al.. (2011). Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck. Recent Patents on Anti-Cancer Drug Discovery. 6(2). 246–257. 6 indexed citations

17.

Baig, Mahadi, et al.. (2010). Calciphylaxis in a Hemodialysis Patient on Corticosteroids and Etanercept for Psoriatic Arthritis. JCR Journal of Clinical Rheumatology. 16(2). 92–93. 2 indexed citations

18.

Raza, Shahzad, et al.. (2009). Adverse clinical sequelae after skin branding: a case series. Journal of Medical Case Reports. 3(1). 25–25. 24 indexed citations

19.

Raza, Shahzad, et al.. (2009). Clostridium Difficile Infection Following Chemotherapy. Recent Patents on Anti-Infective Drug Discovery. 5(1). 1–9. 32 indexed citations

20.

Raza, Shahzad, et al.. (2007). To study hypoactive sexual desire disorder in a fragile X carrier female successfully treated with local testosterone application. International Journal of Impotence Research. 20(2). 226–228. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact